Subject(s)
Antiviral Agents/adverse effects , Cytosine/analogs & derivatives , Ocular Hypotension/chemically induced , Organophosphonates/adverse effects , Pupil Disorders/etiology , Aged , Antiviral Agents/administration & dosage , Cidofovir , Cytosine/administration & dosage , Cytosine/adverse effects , Female , Humans , Infusions, Intravenous , Laryngeal Neoplasms/drug therapy , Organophosphonates/administration & dosage , Papilloma/drug therapy , Tracheal Neoplasms/drug therapySubject(s)
Optic Disk/pathology , Optic Neuritis/etiology , Xanthogranuloma, Juvenile/complications , Adipose Tissue/pathology , Administration, Oral , Diagnosis, Differential , Disease Progression , Dose-Response Relationship, Drug , Drug Administration Schedule , Follow-Up Studies , Glucocorticoids/administration & dosage , Humans , Infant , Magnetic Resonance Imaging , Male , Methylprednisolone/administration & dosage , Optic Neuritis/diagnosis , Optic Neuritis/drug therapy , Orbit , Xanthogranuloma, Juvenile/diagnosis , Xanthogranuloma, Juvenile/drug therapyABSTRACT
INTRODUCTION: myasthenia gravis is a neuromuscular junction disorder that can jeopardize the patient's life and has a high clinical polymorphism that makes it difficult to diagnose. PATIENTS AND METHODS: after reviewing the disease physiology, its clinical symptoms, and the different means to diagnose and treat it, we present a 15-patient series that we cared for at the Rothschild ophthalmologic foundation from 2002 to 2007 for myasthenia gravis that began with isolated ocular symptoms, so as to highlight the clinical diversity of this pathology. RESULTS: when the disease was diagnosed, 11 patients out of 15 had a ptosis with diplopia, two had an isolated ptosis, and two had isolated diplopia. After investigations, we discovered that three patients had a malignant thymoma and one had thymic hyperplasia. An autoimmune disease association was found in two patients: the first one had Hashimoto thyroiditis and the second one developed optical neuromyelitis a few years after his myasthenia gravis. Only three patients secondarily developed a generalized myasthenia gravis. DISCUSSION: our series of patients has a low disease generalization rate in comparison with the published data in the medical literature, indicating that two-thirds of patients with ocular myasthenia gravis should develop generalized myasthenia gravis within approximately 2 years after the beginning of their illness. This could be explained by the early consultation of these patients and the common prescription of an immunosuppressive therapy, reducing the risk of secondarily generalized myasthenia gravis according to some studies. CONCLUSION: despite the small number of patients, this study underlines the clinical polymorphism of ocular myasthenia gravis and the risks it may cause. Close collaboration between ophthalmologists and neurologists is needed to ensure good care for these patients.
Subject(s)
Eye Diseases/etiology , Myasthenia Gravis/complications , Myasthenia Gravis/diagnosis , Adult , Aged , Female , Humans , Male , Middle Aged , Retrospective Studies , Time Factors , Young AdultSubject(s)
Brain Stem Neoplasms/genetics , Electron Transport Complex I/genetics , Glioma/genetics , Mitochondria/genetics , Mitochondrial Proteins/genetics , Mutation/genetics , Tectum Mesencephali/pathology , Brain Stem Neoplasms/diagnosis , Child , Diagnosis, Differential , Glioma/diagnosis , HumansABSTRACT
Ectopia lentis (EL) is a zonular disease where alteration of the zonular fibers leads progressively to lens dislocation. It is most often associated with systemic diseases such as Marfan syndrome, Weill-Marchesani syndrome or homocystinuria. Isolated non syndromic ectopia lentis (IEL) is reported in families with autosomal inheritance, with dominant forms being more common than recessive. LTBP2 truncating mutations have been described as a cause of autosomal recessive ectopia lentis as a primary or secondary feature in patients showing ocular (eg, glaucoma) or extraocular manifestations (eg, Marfanoid habitus). Recently, ADAMTSL4 has been shown to be responsible for isolated autosomal recessive ectopia lentis in an inbred family. Herein we show a consanguineous family that carries a novel homozygous splice mutation IVS4-1G>A/IVS4-1G>A in ADAMTSL4 responsible for isolated autosomal recessive EL, thus confirming the involvement of this gene in this condition and underlining the major role of ADAMTS proteases in zonular fibers homeostasis.
Subject(s)
Codon, Nonsense , Ectopia Lentis/genetics , Genes, Recessive , Thrombospondins/genetics , ADAMTS Proteins , Aphakia, Postcataract/etiology , Aphakia, Postcataract/therapy , Child, Preschool , Consanguinity , DNA Mutational Analysis , Eyeglasses , Functional Laterality , Humans , Lens, Crystalline/surgery , Male , Microsatellite Repeats , Pedigree , Polymerase Chain Reaction , RNA, Messenger/analysis , Visual AcuityABSTRACT
AIMS: Ornithine delta-aminotransferase (OAT) deficiency causes gyrate atrophy (GA) of the retina, as a consequence of high plasma ornithine concentrations. Because creatine synthesis requires the conversion of arginine and glycine into ornithine and guanidinoacetate, high ornithine concentration inhibits this reaction thus causing secondary creatine deficiency. The aim of this study was to evaluate the neuropsychological features and creatine metabolism in patients with GA. METHODS: The study involved 7 GA patients, aged from 11 to 27 years who underwent neuropsychological evaluation and cerebral proton magnetic resonance spectroscopy (MRS). RESULTS: Neurocognitive impairment was found in 5/7 patients, including mental retardation (3/7), school failure (1/7), major visuospatial dyspraxia (1/7), aggressive behavior (3/7) and epilepsy (2/7). Two patients had normal neuropsychological evaluation. Cerebral proton magnetic resonance spectroscopy revealed a profound creatine deficiency in all patients. MRS data were confirmed by decreased levels of creatine and/or guanidinoacetate in plasma and urine in all patients. CONCLUSIONS: In our group of patients with GA, we found a high prevalence of neurological impairment, not reported so far, and possibly related to secondary creatine deficiency and hyperornithinemia. We propose to treat mentally retarded GA patients with high doses of creatine, as it may normalize brain creatine levels and help to reduce ornithine levels.
Subject(s)
Creatine/deficiency , Gyrate Atrophy/complications , Gyrate Atrophy/physiopathology , Ornithine-Oxo-Acid Transaminase/deficiency , Adolescent , Adult , Aggression , Apraxias/etiology , Apraxias/metabolism , Brain/metabolism , Child , Epilepsy/etiology , Epilepsy/metabolism , Female , Gyrate Atrophy/metabolism , Humans , Intellectual Disability/etiology , Intellectual Disability/metabolism , Magnetic Resonance Imaging , Male , Ornithine-Oxo-Acid Transaminase/antagonists & inhibitors , Retrospective Studies , Young AdultABSTRACT
PURPOSE: Discs large (dlg), scribble (scrib), and lethal giant larvae (lgl) are major suppressor genes in Drosophila melanogaster. They encode proteins that regulate cell polarity and cell proliferation in Drosophila and mammals. However, their basic oncogenic roles have not yet been established in mouse epithelial ocular cancer. We evaluated the potential implication of these proteins in tumorigenesis of adenocarcinomas originating from the retinal pigmented epithelium of the Trp1/Tag transgenic mouse model. We examined the changes in the distribution and levels of these proteins in mouse ocular tissues from the Trp1/Tag mouse model. METHODS: The expression patterns of theses genes and their corresponding proteins in normal mouse ocular tissues were studied by in situ hibridization and immunohistofluorescence experiments. In addition, variations in mRNA and proteins levels and protein distributions for Dlg1, Scrib, and Lgl1 were analyzed in the ocular tissues from Trp1/Tag transgenic mouse model by reverse transcription polymerase chain reaction (RT-PCR), western blot analysis, and immunohistofluorescence. RESULTS: We found that mouse Dlg1, Scrib, and Lgl1 are widely distributed in normal ocular tissues, particularly in retinal neurons. We found that the three proteins are mislocalized in retinal layers during ocular carcinogenesis. These mislocalizations were correlated to the early dysplastic stages of ocular tumorigenesis. Additionally, the mislocalization of each protein was associated with its downregulation. Decreased levels of these proteins may be considered as late-stage markers of the disease but also as markers of the invasive stage of this cancerous process. This downregulation may be involved in epithelial-mesenchymal transition in this mouse ocular tumoral model. This would be consistent with the downregulation of E-cadherin and upregulation of N-cadherin expression observed in this model. CONCLUSIONS: This is the first study to demonstrate the involvement of Dlg1, Scrib, and Lgl1 in a mouse with ocular adenocarcinoma and the simultaneous involvement of these proteins in the same cancer. Our results indicate that both the mislocalization and downregulation of these proteins may be involved together in ocular carcinogenesis.
Subject(s)
Disease Models, Animal , Eye Neoplasms/genetics , Gene Expression Regulation, Neoplastic , Glycoproteins/genetics , Intracellular Signaling Peptides and Proteins/genetics , Nerve Tissue Proteins/genetics , Animals , Cadherins/genetics , Cadherins/metabolism , Discs Large Homolog 1 Protein , Disease Progression , Down-Regulation/genetics , Eye Neoplasms/pathology , Immunohistochemistry , Mice , Mice, Transgenic , Nerve Tissue Proteins/metabolism , Protein Transport , RNA, Messenger/genetics , RNA, Messenger/metabolism , Retina/metabolism , Retina/pathology , SAP90-PSD95 Associated Proteins , Transcription, GeneticABSTRACT
PURPOSE: Choroidal melanoma is the most common primary malignant ocular tumor in human adults. Relevant mouse models of human uveal melanoma still remain to be developed. We have studied the transgenic mouse strain, Tyrp-1-TAg, to try to gain insight into possible molecular mechanisms common to pigmented ocular neoplasms occurring spontaneously in the eyes of these mice and human choroidal melanoma. The role of two members of the ETS (E26 avian leukemia oncogene) family of transcription factors, ETS-1 and ETS-2, has been investigated in many cancers but has not yet been studied in ocular tumors. METHODS: This is the first study describing the production and distribution of ETS-1 and ETS-2 mRNAs and proteins using in situ hybridization and immunohistochemistry in murine ocular tissue sections of normal control eyes and tumoral eyes from mice of the same age. Using semi-quantitative reverse-transcription polymerase chain reaction (RT-PCR) and western blots experiments, we compared changes in ETS-1 and ETS-2 expression, their protein levels, and the regulation of some of their target gene expressions at different stages of the ocular tumoral progression in the transgenic mouse model, Tyrp-1-TAg, with those in normal eyes from control mice of the same age. RESULTS: In normal control adult mouse eyes, ETS-1 was mostly present in the nuclei of all neuroretinal layers whereas ETS-2 was mostly localized in the cytosol of the cell bodies of these layers with a smaller amount present in the nuclei. Both were found in the retinal pigmentary epithelium (RPE). ETS-1 and ETS-2 mRNA and protein levels were much higher in the ocular tissues of Tyrp-1-TAg mice than in control ocular tissues from wild-type mice. This upregulation was correlated with tumor progression. We also demonstrated upregulation of ETS-1 and ETS-2 target expressions in Tyrp-1-TAg mice when comparing with the same target expressions in control mice. CONCLUSIONS: Our findings suggest that ETS-1 and ETS-2 are upregulated in ocular tumors derived from the retinal epithelium and may be involved in one or several signaling pathways that activate the expression of a set of genes involved in ocular tumor progression such as those encoding ICAM-1 (intercellular adhesion molecule-1), PAI-1 (Plasminogen activator inhibitor-1), MCP-1 (monocyte chemoattractant protein-1) and p16 (Cyclin dependent kinase inhibitor 2A).
Subject(s)
Eye Neoplasms/genetics , Gene Expression Regulation, Neoplastic , Pigmentation/genetics , Proto-Oncogene Protein c-ets-1/genetics , Proto-Oncogene Protein c-ets-2/genetics , Up-Regulation/genetics , Animals , Chemokine CCL2/genetics , Chemokine CCL2/metabolism , Cyclin-Dependent Kinase Inhibitor p16/genetics , Cyclin-Dependent Kinase Inhibitor p16/metabolism , Disease Models, Animal , Eye/metabolism , Eye/pathology , Eye Neoplasms/metabolism , Eye Neoplasms/pathology , Humans , Intercellular Adhesion Molecule-1/genetics , Intercellular Adhesion Molecule-1/metabolism , Mice , Mice, Transgenic , Plasminogen Activator Inhibitor 1/genetics , Plasminogen Activator Inhibitor 1/metabolism , Protein Transport , Proto-Oncogene Protein c-ets-1/metabolism , Proto-Oncogene Protein c-ets-2/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolismABSTRACT
INTRODUCTION: Surgical possibilities in superior oblique palsy are numerous. The aim of this study was to evaluate the results of a 12-mm inferior oblique recession in each cardinal position of gaze. PATIENTS AND METHODS: Six patients suffering from superior oblique palsy were studied. All of them presented disabling symptoms such as right-left incomitance, and hypertropia in primary gaze equal to or lower than 25 diopters. They all underwent a pre- and postoperative deviometry. The surgical protocol was a 12-mm inferior oblique muscle recession, with reinsertion 4 mm behind the inferior rectus. RESULTS: Functional results were positive. Mean hypertropia in primary gaze was 14.7 diopters for far and 12.7 diopters for near vision. The reduction of hypertropia in primary gaze was approximately 10 diopters, corresponding to 71.6% for far and 81.4% hypertropia for near vision. The mean postoperative vertical deviation was equal to 4.2 diopters for far and 2.3 diopters for near vision. Results in adduction were good even if there was a high level of hypertropia in this gaze position. CONCLUSION: Many authors suggest considering anatomic abnormalities to improve surgical results such as traction testing on the oblique superior and superior rectus muscles. We can suggest a first-intention 12-mm recession of the inferior oblique muscle in cases of right-left incomitance with hypertropia in primary gaze lower than 25 diopters.
Subject(s)
Ocular Motility Disorders/surgery , Oculomotor Muscles/abnormalities , Oculomotor Muscles/surgery , Oculomotor Nerve Diseases/surgery , Ophthalmoplegia/surgery , Humans , Retrospective Studies , Treatment Outcome , Vision, BinocularABSTRACT
PURPOSE: Asymmetric cell division (ACD) is the fundamental mechanism underlying the generation of cellular diversity in invertebrates and vertebrates. During Drosophila neuroblast division, this process involves stabilization of the apical complex and interaction between the Inscuteable (Insc) and Partner of inscuteable (Pins) proteins. Both cell-intrinsic factors and cell-cell interactions seem to contribute to cell fate decisions in the retina. The Pins protein is known to play a major role in the asymmetric segregation of cell fate determinants during development of the central nervous system in general, but its role in asymmetric cell divisions and retinoblast cell fate has never been explored. The primary aim of this study was to determine the spatial distribution and time course of mouse homolog of Drosophila Partner of Inscuteable (mPins) expression in the developing and adult mouse eye. METHODS: The expression pattern of mPins was studied in the mouse eye from embryonic (E) stage E11.5 until adulthood, by semiquantitative RT-PCR, in situ hybridization, and immunohistochemistry. In addition, variations in mRNA and protein levels for mPins were analyzed in the developing postnatal and adult lens, by semiquantitative RT-PCR, western blot analysis, in situ hybridization, and immunohistochemistry. RESULTS: We detected mPins mRNA at early stages of mouse embryonic eye development, particularly in the neuroblastic layer. In early postnatal development, mPins mRNA was still detected in the neuroblastic layer, but also began to be detectable in the ganglion cell layer. Thereafter, mPins mRNA was found throughout the retina. This pattern was maintained in differentiated adult retina. Immunohistochemical studies showed that mPins protein was present in the neuroblastic layer and the ganglion cell layer during the early stages of postnatal retinal development. At these stages, mPins protein was colocalized with Numb protein, a marker of the ACD. At later postnatal stages, mPins protein was present in all retinal nuclear layers and in the inner plexiform layer. It continued to be detected in these layers in the differentiated retina; the outer plexiform layer and the photoreceptor inner segments also began to display positive immunostaining for mPins. In the adult retina, mPins was also detected in the retinal pigment epithelium and choroidal melanocytes. Throughout development, mPins protein was detected in nonretinal tissues, including the cornea, ciliary body, and lens. We focused our attention on lens development and showed that mPins protein was first detected at E14.5. The most striking results obtained concerned the lens, in which mPins protein distribution switched from the anterior to the posterior region of the lens during embryonic development. Interestingly, in the postnatal and adult lens, mPins protein was detected in all lens cells and fibers. CONCLUSIONS: We provide the first demonstration that mPins protein is expressed from embryonic stages until adulthood in the mouse eye. These results suggest that mPins plays important roles in eye development. This work provides preliminary evidence strongly supporting a role for mPins in the asymmetric division of retinoblasts, and in the structure and functions of adult mouse retina. However, the link between the presence of mPins in different ocular compartments and the possible occurrence of asymmetric cell divisions in these compartments remains to be clarified. Further studies are required to elucidate the in vitro and in vivo functions of mPins in the developing and adult human eye.
Subject(s)
Adaptor Proteins, Signal Transducing/genetics , Eye/embryology , Eye/metabolism , Gene Expression Regulation, Developmental , Adaptor Proteins, Signal Transducing/metabolism , Animals , Animals, Newborn , Antibodies , Cell Differentiation , Ciliary Body/cytology , Ciliary Body/metabolism , Embryo, Mammalian/cytology , Embryo, Mammalian/metabolism , Eye/cytology , Immunohistochemistry , In Situ Hybridization , Lens, Crystalline/cytology , Lens, Crystalline/embryology , Lens, Crystalline/metabolism , Membrane Proteins/metabolism , Mice , Mice, Inbred C57BL , Nerve Tissue Proteins/metabolism , Protein Transport , RNA Transport , RNA, Messenger/genetics , RNA, Messenger/metabolism , Retina/cytology , Retina/embryology , Retina/metabolismABSTRACT
Nutritional deficiency may be the cause of a genuine optic neuropathy, sometimes associated with involvement of the peripheral nervous system. Nutritional optic neuropathies are usually bilateral, painless, chronic, insidious and slowly progressive. Most often, they present as a non-specific retrobulbar optic neuropathy. The differential diagnosis with other causes of optic nerve involvement, in particular of toxic origin, may be particularly difficult. Nutritional deficits are often associated with toxic effects from alcohol and tobacco; therefore, the separation of the nutritional and toxic components is often illusory and artificial. The pathophysiological mechanisms involved in nutritional -- and toxic -- optic neuropathies affect biochemical pathways involved in cell energetic production, correction of oxidative stress and quenching of free radicals. The recognition of these mechanisms could provide future therapeutic alternatives. Currently, the treatment is limited to the intensive use of vitamins with variable results in individual cases, and to the implementation of preventive measures, when feasible.
Subject(s)
Malnutrition/complications , Malnutrition/metabolism , Neurotoxicity Syndromes/etiology , Neurotoxicity Syndromes/metabolism , Optic Nerve Diseases/etiology , Optic Nerve Diseases/metabolism , Diagnosis, Differential , Energy Metabolism/drug effects , Energy Metabolism/physiology , Ethanol/toxicity , Humans , Malnutrition/physiopathology , Neurotoxicity Syndromes/diagnosis , Optic Nerve/drug effects , Optic Nerve/metabolism , Optic Nerve/physiopathology , Optic Nerve Diseases/diagnosis , Oxidative Stress/drug effects , Oxidative Stress/physiology , Nicotiana/toxicityABSTRACT
The persistence of the fetal vascular system is a rare ocular malformation whose origin remains unknown. It comprises a group of complex ocular malformations from which the various clinical forms have a heterogeneous functional prognosis. The diagnosis depends on a precise and complete examination of the child's eye, often under general anesthesia. Various clinical forms can be found together, ranging from the tiny form with no visual repercussion or ocular or systemic anomaly associated with the major forms involving the totality of the ocular structures and systemic syndromes. A systematic general pediatric examination is therefore recommended. The treatment is adapted individually for early and specific surgical and medical treatment. In the event of intervention, the induced aphakia will be corrected in one procedure with an implantation, generally sutured with the sclera, or at the time of a second intervention after the wearing of glasses or a contact lens. However, the complications can sometimes lead to rapid phthisis bulbi. Whatever solution is chosen, the final functional result has progressed thanks to early diagnosis, the surgical techniques suggested, even if implantation continues to be debated. Amblyopia must be treated for the entire sensitive period. However, despite good rehabilitation, the average functional prognosis remains disappointing, probably because of the overall ocular malformation.
Subject(s)
Eye Abnormalities/embryology , Vitreous Body/abnormalities , Abnormalities, Multiple , Amblyopia/etiology , Amblyopia/therapy , Aphakia/congenital , Aphakia/etiology , Child, Preschool , Diagnostic Techniques, Ophthalmological , Eye Abnormalities/diagnosis , Eye Abnormalities/surgery , Female , Humans , Hyperplasia , Infant , Infant, Newborn , Lens Implantation, Intraocular , Lens, Crystalline/blood supply , Lens, Crystalline/embryology , Male , Postoperative Complications , Ultrasonography , Vitrectomy , Vitreous Body/blood supply , Vitreous Body/diagnostic imaging , Vitreous Body/embryology , Vitreous Body/surgeryABSTRACT
OBJECTIVES: The persistence and hyperplasia of the primary vitreous is a rare ocular malformation whose origin remains unknown. The goal of this study was to retrospectively analyze the records of the children followed in our department and to note sex, antecedents, age and reason for the first consultation, side and ocular structures involved, treatment, follow-up, complications, and progression. METHODS: The initial clinical examination was noted and completed by the examination under general anesthesia and the surgical or nonsurgical treatment proposed. RESULTS: Fifty-six eyes of 52 children were included: 19 anterior forms, four posterior, 25 mixed, and eight eyes already operated on in other centers. Fifty eyes had surgical treatment. At the end of follow-up, 13 eyes had a vision equal to or greater than 20/200 (23%) including five that were better than 20/100 (9%). Average follow-up was 32.5 months. CONCLUSIONS: Persistence of the fetal vascular system is a group of complex ocular malformations requiring an early diagnosis and well-adapted management.
Subject(s)
Vitrectomy , Vitreous Body/abnormalities , Vitreous Body/surgery , Cataract Extraction , Child , Follow-Up Studies , Humans , Hyperplasia , Lens Implantation, Intraocular/statistics & numerical data , Retrospective Studies , Time Factors , Visual Acuity , Vitreous Body/pathologyABSTRACT
Anhidrotic ectodermal dysplasia is a congenital, generally X-linked dermatosis that associates facial dysmorphy, short stature, and severe blepharitis. The anomalies of the skin are epidermic abnormalities; reduction of the glands of the derm, particularly the sweat glands, explaining the hypohidrosis; onychodysplasia; trichodysplasia; and abnormal dentition. The ophthalmologic manifestations are palpebral anomalies with a reduction in or an absence of Meibomian glands, dysfunction of the Moll and Zeis glands, leading to chronic squamous blepharitis and lacrimal punctal atresia. These anomalies result in severe attacks of the ocular surface, developing during the second decade, which are often invalidating and require a rigorous follow-up to avoid corneal complications.
Subject(s)
Ectodermal Dysplasia 1, Anhidrotic/diagnosis , Eye Abnormalities/diagnosis , Lacrimal Apparatus/abnormalities , Adolescent , Chromosomes, Human, X , Corneal Diseases/epidemiology , Corneal Diseases/prevention & control , Humans , Hypohidrosis , Meibomian Glands/abnormalities , Skin Abnormalities/etiologyABSTRACT
Fabry's disease is a rare X-linked inborn error of glycosphingolipid metabolism characterised by an abnormal lipid storage due to a defect of lysozomal alphagalactosidase. The consequence is a storage of glycosphingolipides in all tissues. This storage in vessels's endothelial cells is responsible, in males, for severe ischemic lesions leading to progressive kidney failure, cardiac and cerebral dysfunctions. Similarly, it involves ocular tissues, mainly the cornea, the conjunctiva and the lens. The corneal storage, known as cornea verticillata, is a clinical marker easy to recognize by slit lamp examination of the affected males and carrier females. The enzymatic activity of alphagalactosidase is reduced in tears. Characteristic lamellar bodies can be observed by electron microscopy study of a conjunctival biopsy. Until recently, treatment was limited to symptomatic management of pain, and end-stage complications of renal failure, cardiac or brain disease. Recent studies have demonstrated that enzyme replacement therapy by genetic engineering is now shown to be promising for affected patients.
Subject(s)
Fabry Disease , Child , Eye Diseases/etiology , Fabry Disease/complications , Fabry Disease/diagnosis , Fabry Disease/genetics , Fabry Disease/therapy , Female , Humans , Male , PedigreeABSTRACT
In children with painful ophthalmoplegia, the diagnosis of Tolosa-Hunt syndrome or of ophthalmoplegic migraine should only be considered when tumoral, infectious, inflammatory or vascular causes have been excluded by appropriate investigations. Both entities are classified as "neuralgia" by the International Headache Society, and seem to share a similar pathogenic mechanism. Both diseases have many clinical similarities with slight differences concerning pain characteristics or ocular associated symptoms. High resolution CT scan or contrast enhanced MRI can be necessary to exclude other causes of painful ophthalmoplegia. They can sometimes objectify an inflammatory process of the cavernous sinus in Tolosa-Hunt syndrome or a reversible enhancement and thickening of the cisternal segment of the oculomotor nerve during an ophthalmoplegic migraine. Pain and ophthalmoplegia quickly resolve with corticosteroids. Such treatment may decrease the risk of recurrence. It is important to follow-up these patients for a 2 years period and to repeat the etiologic assessment. We report here 2 cases of children with painful ophtalmoplegia.
Subject(s)
Migraine Disorders/diagnosis , Ophthalmoplegia/etiology , Pain/etiology , Tolosa-Hunt Syndrome/diagnosis , Adolescent , Adrenal Cortex Hormones/therapeutic use , Child, Preschool , Diclofenac/therapeutic use , Female , Humans , Male , Ophthalmoplegia/complications , Ophthalmoplegia/drug therapy , Pain/drug therapyABSTRACT
PURPOSE: The mutations responsible for Best vitelliform macular dystrophy (BVMD) are found in a gene called VMD2. The VMD2 gene encodes a transmembrane protein named bestrophin-1 (hBest1) which is a Ca(2+)-sensitive chloride channel. This study was performed to identify disease-specific mutations in 27 patients with BVMD. Because this disease is characterised by an alteration in Cl(-) channel function, patch clamp analysis was used to test the hypothesis that one of the VMD2 mutated variants causes the disease. METHODS: Direct sequencing analysis of the 11 VMD2 exons was performed to detect new abnormal sequences. The mutant of hBest1 was expressed in HEK-293 cells and the associated Cl(-) current was examined using whole-cell patch clamp analysis. RESULTS: Six new VMD2 mutations were identified, located exclusively in exons four, six and eight. One of these mutations (Q293H) was particularly severe. Patch clamp analysis of human embryonic kidney cells expressing the Q293H mutant showed that this mutant channel is non-functional. Furthermore, the Q293H mutant inhibited the function of wild-type bestrophin-1 channels in a dominant negative manner. CONCLUSIONS: This study provides further support for the idea that mutations in VMD2 are a necessary factor for Best disease. However, because variable expressivity of VMD2 was observed in a family with the Q293H mutation, it is also clear that a disease-linked mutation in VMD2 is not sufficient to produce BVMD. The finding that the Q293H mutant does not form functional channels in the membrane could be explained either by disruption of channel conductance or gating mechanisms or by improper trafficking of the protein to the plasma membrane.